Patents for A61P 39 - General protective or antinoxious agents (19,019)
07/2002
07/24/2002CN1087947C 'Shencaosanye' tea
07/24/2002CN1087945C Traditional Chinese medicine prepn. for giving-up drug
07/24/2002CN1087937C Medicine of inhibiting Alzheimer's disease
07/23/2002US6423855 Prevention lysis; oxidation resistance
07/23/2002US6423750 Systems for delivering anti-infective compositions to treat disordered tissue such as cold sores
07/18/2002WO2002055067A2 Fumaric acid derivatives as nf-kappab inhibitors
07/18/2002WO2002055066A1 Fumaric acid derivatives as nf-kappa-b inhibitors
07/18/2002WO2002055049A1 Cosmetic and/or pharmaceutical preparations
07/18/2002WO2002055048A1 Cosmetic and/or pharmaceutical preparations
07/18/2002WO2002034202A3 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress
07/18/2002US20020094998 Methods and compositions for treatment of ocular neovascularization and neural injury
07/18/2002CA2428075A1 Fumaric acid derivatives as nf-kappab inhibitors
07/17/2002EP1221959A2 Use of parvoviruses for improving the general condition of tumour patients or patients having chronic or consumptive diseases
07/17/2002EP1221868A1 Dietary supplement
07/17/2002CN1358720A Three-site substituted beta-carboline novel compound having anti-HIV and anti-cancer activity
07/17/2002CN1087611C Oral nutrient lead-expelling powdered granules
07/16/2002US6420431 Methods for treating disordered tissue through agitated delivery of anti-infective compositions
07/16/2002US6420393 Nuclear factor .kappa.b-dependent disease selected from the group consisting of inflammatory diseases, immunological disorders, septic shock, transplant rejection, radiation damage, reperfusion injuries after ischemia, stroke or
07/16/2002US6420373 9-N-Bicyclic nuceoside agents useful as selective inhibitors of proinflammatory cytokines
07/16/2002US6420342 Ribose, folic acid, orotic acid
07/16/2002US6419919 Method for the augmentation of gene expression
07/11/2002WO2002053770A2 Method for the prediction of the risk potential for cancerous diseases and inflammatory intestinal diseases and corresponding tests
07/11/2002WO2002053130A2 Sustained release drug delivery devices with coated drug cores
07/11/2002WO2002053110A2 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body
07/11/2002WO2002036605A3 Estrone-derivatives having cytoprotective activity
07/11/2002WO2000075144A9 Peroxynitrite decomposition catalysts and methods of use thereof
07/11/2002WO2000064911A9 Ligands for metabotropic glutamate receptors
07/11/2002US20020091266 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress
07/11/2002US20020090624 Gene markers useful for detecting skin damage in response to ultraviolet radiation
07/11/2002US20020090373 ADAMTS polypeptides, nucleic acids encoding them, and uses thereof
07/11/2002CA2433552A1 Pharmaceutical preparation for douches and/or irrigations of natural or pathological cavities in the human body
07/10/2002EP1221477A2 Transfection of vertebrate cells e.g. by homologous recombination
07/10/2002EP1221326A2 Nitric oxide donors capable of reducing toxicity from drugs
07/10/2002EP1220869A1 Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
07/10/2002EP1220865A1 43 human secreted proteins
07/10/2002CN1358178A Pharmaceutical compounds
07/10/2002CN1357325A Prepn of natural active body cell multiplication promoter
07/09/2002US6417173 Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
07/04/2002WO2002051442A1 Concomitant drugs
07/04/2002WO2002028347A3 Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
07/04/2002WO2001091682A8 Composition and applicator for topical substance delivery
07/04/2002WO2000069891A9 Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins
07/04/2002US20020086864 Administering optically pure (S,S) enantiomer of reboxetine
07/04/2002US20020086051 For delivering drug directly to interior portions of the body of a mammalian organism, such as to the eye
07/04/2002US20020085995 In vivo induction for enhanced function of isolated hepatocytes
07/04/2002DE10063294A1 New N-(heterocyclyl-alkyl)-fused norbornylamine derivatives, are NHE3 inhibitors useful e.g. for treating respiratory disorders, renal failure, intestinal dysfunction, lipid metabolism disorders or proliferative diseases
07/04/2002CA2436739A1 Combination agent
07/03/2002EP1219180A1 Cancer chemoprotective food products
07/03/2002EP1218333A1 Anti-inflammatory nitro- and thia- fatty acids
07/03/2002EP1218000A1 Anti-cancer nitro- and thia-fatty acids
07/03/2002EP1217983A1 Skincare composition against free radicals
07/03/2002CN1356981A Pharmaceutical compounds
07/02/2002US6414114 Useful as agents in oxidation-reduction equilibrium in cells; enzyme regulation in homeostasis
07/02/2002US6414032 Anti-infective compositions for treating disordered tissue such as cold sores
06/2002
06/27/2002WO2002050255A2 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof
06/27/2002WO2002050107A2 Streptococcus pyogenes antigens and corresponding dna fragments
06/27/2002WO2002050032A1 Naphthalene derivatives which bind to the ep4 receptor
06/27/2002WO2002050027A1 Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
06/27/2002WO2002049575A2 Method and composition for the treatment of diabetic neuropathy
06/27/2002WO2001094381A3 Novel compounds of the n-acylamino-amide family, compositions comprising same, and uses
06/27/2002WO2001076584A3 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
06/27/2002US20020082256 Compounds useful as anti-inflammatory agents
06/27/2002CA2789252A1 Streptococcus pyogenes antigens and corresponding dna fragments
06/27/2002CA2432760A1 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof
06/26/2002EP1217068A2 Oil palm (genus Elaeis) peroxiredoxin gene and uses thereof
06/26/2002EP1217007A2 Serum paraoxonase
06/26/2002EP1216247A1 Imidazoimidazoles and triazoles as anti-inflammatory agents
06/26/2002EP1216043A1 Retard form containing alpha-lipoic acid (derivatives)
06/26/2002EP1216026A1 Compositions of tocol-soluble therapeutics
06/26/2002CN1355807A Thiazoloindolinone compounds
06/26/2002CN1355802A Substituted porphyrins
06/26/2002CN1355708A HCV combination therapy containing ribavirin in association with antioxidants
06/26/2002CN1355695A Compounds useful in reducing level of insulin like growth factor-I (IGF-I) in blood
06/26/2002CN1355672A Method of increasing content of flavonoids and phenolic substances in plants
06/26/2002CN1086584C Medicine for preventing chronic lead poisoning
06/25/2002US6410599 Mixture of benzalkonium chloride, water and isopropanol
06/25/2002US6410289 Isolated human dehydrogenases, nucleic acid molecules encoding these human dehydrogenases, and uses thereof
06/25/2002CA2215210C Polyphenol fractions of tea, the use thereof and formulations containing them
06/20/2002WO2002048337A2 Secreted human proteins
06/20/2002WO2002048117A1 Quinazolinone derivatives
06/20/2002WO2002047687A1 Urotensin-ii receptor antagonists
06/20/2002WO2002047656A1 Compositions for retarding skin aging
06/20/2002WO2002047493A2 Health promoting compositions
06/20/2002WO2002047456A2 Urotensin-ii receptor antagonists
06/20/2002WO2001056590A3 Utilization of protein kinase inhibitor alpha
06/20/2002DE10060292A1 Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament Use of substituted benzimidazoles for the manufacture of a medicament for the treatment of diseases which can be influenced by inhibiting the Na + / H + exchanger and containing medicament
06/20/2002CA2431406A1 Quinazolinone derivatives
06/20/2002CA2428216A1 Secreted proteins
06/19/2002EP1214422A1 Phosphatases which activate map kinase pathways
06/19/2002EP1214335A1 Gamma-carboxyglutamate containing conopeptides
06/19/2002EP1214084A2 An anti-oxidant preparation based on plant extracts for the treatment of circulation and adiposity problems
06/19/2002EP1214064A1 Systems for agitated delivery of anti-infective compositions to treat disordered tissue such as cold sores
06/19/2002EP1165596B1 14,15-alpha-methylene equilenine derivatives, methods for producing the same and medicaments containing them
06/19/2002CN1354740A Pharmaceutical compounds
06/19/2002CN1354657A EGF-R antagonists for treating hypersecretion of mucus in lungs
06/18/2002US6407278 Stable amorphous amifostine compositions and methods for the preparation and use of the same
06/18/2002US6407133 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
06/13/2002WO2002046208A2 Method of producing biospecific molecules by protein trans-splicing
06/13/2002WO2002046169A1 Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors
06/13/2002WO2002045728A1 Cosmetic and/or dermopharmaceutical preparations containing leaf extracts of the plant argania spinosa